Boston Scientific’s carotid Wallstent Monorail endoprosthesis with FilterWire EZ Embolic protection system has been found to be safe for high surgical risk patients in routine clinical practice.

The carotid Wallstent Monorail endoprosthesis is a self-expanding, flexible, low-profile stent delivery system designed to provide increased scaffolding for improved lesion coverage and a smooth inner lumen.

The multicentre CABANA post-approval study enrolled 1,097 patients and showed that carotid artery stenting with the carotid Wallstent and FilterWire EZ is a safe alternative to carotid endarterectomy in patients with carotid artery stenosis.

In the study, the primary endpoints included stroke, death and myocardial infarction, of 4.6%.

Trial investigator Nelson Hopkins said data from the post-approval study show low rates of stroke, death, and myocardial infarction, demonstrating that the carotid Wallstent and FilterWire EZ can be used in carotid stenting procedures as a safe alternative to surgery in high-risk patients.

"In my clinical practice, I have found that the user-friendly design of this stenting system contributes to successful outcomes in patients with carotid artery stenosis at increased risk for surgery," Hopkins added.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The findings from the study were presented at the Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco, US.